Skip to content

Advertisement

  • Poster presentation
  • Open Access

A review of the online prognositc model predict using the POSH cohort (women aged ≤40 years at breast cancer diagnosis)

  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 1,
  • 3,
  • 2 and
  • 3
Trials201516 (Suppl 2) :P36

https://doi.org/10.1186/1745-6215-16-S2-P36

  • Published:

Keywords

  • Breast Cancer
  • Young Woman
  • Large Cohort
  • Common Cancer
  • Early Breast Cancer

Introduction

Breast cancer is the most common cancer women in the UK, with approximately 50,000 new cases each year. PREDICT (http://www.predict.nhs.uk) is an online prognostic tool developed to help determine the best available treatment and long-term outcome for early breast cancer. This study was conducted to establish how well PREDICT performs in estimating survival in a large cohort of younger women (aged ≤40 years) recruited to the POSH study.

Methods

The UK POSH cohort includes data from 3000 women aged ≤40 years at breast cancer diagnosis. Study endpoints were overall- and breast cancer specific-survival at 5-,8-, and 10-years. Evaluation of PREDICT included model discrimination and comparison of the number of predicted versus observed events.

Results

PREDICT provided accurate long term (8- and 10-year) survival estimates for younger women. However, short term (5-year) estimates were less accurate, with the tool overestimating survival by 25%, and by 56% for patients with ER positive tumours. PREDICT also underestimated survival at 5-years for patients with ER negative tumours.

Conclusions

PREDICT is a user-friendly and reliable tool for providing accurate long-term survival estimates for younger women with breast cancer. However, the model requires further calibration for more accurate short-term estimates. Prediction in the short-term may be most relevant for the increasing number of women considering risk-reducing bilateral mastectomy.

Declarations

Acknowledgements

Funding for data collection/analysis of the POSH study by CRUK (grants A7572, A11699, C1275/A15956). Study sponsored by UHS NHS Foundation Trust. We also thank the NIHR NCRN for supporting patient recruitment and all participating patients.

Authors’ Affiliations

(1)
Cancer Sciences Academic Unit and University of Southampton Clinical Trials Unit, Southampton, UK
(2)
Department of Oncology, University of Cambridge, Cambridge, UK
(3)
Faculty of Medical Science, Anglia Ruskin University, Cambridge, UK

Copyright

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement